Having trouble accessing articles? Reset your cache.

AGT-182: Phase I started

ArmaGen began an open-label, dose-escalation, U.S. Phase I trial to evaluate

Read the full 117 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE